These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32557192)

  • 1. Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease.
    An JN; Joo SK; Koo BK; Kim JH; Oh S; Kim W
    Hepatol Int; 2020 Sep; 14(5):798-807. PubMed ID: 32557192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
    Park JH; Koo BK; Kim W; Kim WH;
    Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
    Singh S; Allen AM; Wang Z; Prokop LJ; Murad MH; Loomba R
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):643-54.e1-9; quiz e39-40. PubMed ID: 24768810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver is not associated with incident chronic kidney disease: a large histology-based comparison with healthy individuals.
    Choudhary NS; Saraf N; Kumar N; Rai R; Saigal S; Gautam D; Lipi L; Rastogi A; Goja S; Bhangui P; Ramchandra SK; Soin AS
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):441-3. PubMed ID: 26636408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
    Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
    PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.
    Brunt EM; Kleiner DE; Wilson LA; Unalp A; Behling CE; Lavine JE; Neuschwander-Tetri BA;
    Hepatology; 2009 Mar; 49(3):809-20. PubMed ID: 19142989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 14. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease.
    Machado MV; Gonçalves S; Carepa F; Coutinho J; Costa A; Cortez-Pinto H
    Liver Int; 2012 Feb; 32(2):241-8. PubMed ID: 22098270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients.
    Wang Y; Yu Y; Wan H; Chen Y; Xia F; Zhang W; Zhang K; Gu X; Zhang Y; Lin Z; Yu Y; Wang N; Lu Y
    Diabetes Metab Res Rev; 2020 Jul; 36(5):e3294. PubMed ID: 32017389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression.
    Fontes-Cal TCM; Mattos RT; Medeiros NI; Pinto BF; Belchior-Bezerra M; Roque-Souza B; Dutra WO; Ferrari TCA; Vidigal PVT; Faria LC; Couto CA; Gomes JAS
    Front Immunol; 2021; 12():708959. PubMed ID: 34447378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm.
    Cho Y; Lim SK; Joo SK; Jeong DH; Kim JH; Bae JM; Park JH; Chang MS; Lee DH; Jung YJ; Kim BG; Kim D; Lee KL; Kim W
    Liver Int; 2019 Sep; 39(9):1722-1731. PubMed ID: 31162812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal impairment is prevalent in pediatric NAFLD/MASLD and associated with disease severity.
    Mouzaki M; Yates KP; Arce-Clachar AC; Behling C; Blondet NM; Fishbein MH; Flores F; Adams KH; Hertel P; Jain AK; Molleston JP; Schwimmer JB; Vos MB; Xanthakos SA;
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):238-249. PubMed ID: 38828720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia.
    Mehta A; Lee TB; Alebna P; Grandhi GR; Dixon DL; Salloum FN; Sanyal AJ; Siddiqui MS
    J Clin Lipidol; 2023; 17(6):828-833. PubMed ID: 37957050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.